The rediscovery began in 2013, when a single adult specimen was found at East Creech Farm, Dorset, by Rachel Terry. Dissection of the genitalia confirmed the moth was indeed T. nigripunctella and not the superficially identical European species T. rhenania. Since then, adults have been seen annually in a small area of Dorset, and between 2014 and 2024 the species has been recorded at one coastal and two inland locations roughly 40 kilometres west of the 2013 site. The new study, published in Nota Lepidopterologica, reviews these modern records alongside historical specimens held in the Natural History Museum, London, documenting the moth’s prior distribution across southern England from Kent to Cornwall and north to Cheshire and Yorkshire, with records also from the Channel Islands, Ireland, and doubtfully Northumberland.

The breakthrough came in July 2023, when observers noticed adults flying close to stone walls, including a dry-stone wall and a mortared wall. On 5 July 2023, an adult was seen flying near a small hole in a mortared wall, with two apparently fresh adults sitting at the entrance to the same hole, suggesting they might have emerged from pupae within it. A large snail shell was visible at the entrance. The hole was no deeper than 15 centimetres. This observation provided the first clue that the larvae might be developing inside dead snail shells, a hypothesis that subsequent searching would confirm in remarkable detail.

Careful examination of dead snail shells lying on ledges, windowsills, and within the wall hole revealed larval frass on seven occasions, in shells identified as the Garden Snail Cornu aspersum and the White-lipped Snail Cepaea hortensis. Each of the two Cornu shells contained a living larva. One was successfully reared to the adult stage, while the other died, but its identity was confirmed from its DNA barcode. When the shells were carefully cut open, the larvae were found close to the centre, with silk and frass distributed within. The blackish gut contents of the larvae and the blackish frass found in the shells almost certainly indicate that the larvae feed on the dried body tissues of the snails, making this the first observation inferring dead molluscan tissue as a food source for a lepidopteran larva in Great Britain.

The final instar larva is translucent whitish or cream-coloured, sometimes tinged yellowish, with dark gut contents often visible through the body wall. The head is translucent pale brown or orangey brown, the prothoracic plate yellowish, and the setae whitish and long, approximately the diameter of the body. Larvae spend most of their time within a delicate silken tube adorned with frass and detritus. Prior to pupation they construct a whitish silken cocoon densely covered with frass and detritus, affixed horizontally to a surface or made within a snail shell. The pupa is over 5 millimetres long, pale brown, and exarate, with antennal appendages extending just beyond the end of the abdomen and dorsal abdominal spines present.

Beyond snail shells, larvae very likely to be Tenaga were also found in silken tubes at the base of stacked plant pots and seed trays containing a scattering of detritus including mouse faeces, dead invertebrates, plant and mineral debris, and spider cobwebs. Traces of likely feeding were observed on dry mouse droppings, where the surface appeared eaten away, and a larva was found within a dead Western Honeybee Apis mellifera. However, no direct observation of feeding has yet been made, and caution is expressed over concluding that all larvae observed were Tenaga, since larvae of the White-shouldered House-moth Endrosis sarcitrella were also found and reared from the same locations. The two species are superficially very similar, especially before the final instar, although unlike E. sarcitrella, the prothoracic plate of T. nigripunctella lacks a median suture. Further work is required to separate these species reliably in the field.

The larvae proved to be quite active, able to move outside their silken tubes many tens of centimetres over several minutes, suggesting they can readily move between food sources in the wild. This mobility fits with observations of frass but no larvae within other snail shells, indicating that larvae may graze one shell and move on to the next. Adult behaviour is equally distinctive. The moth rests characteristically in an inclining posture at about 30 degrees, raised up on extended forelegs and midlegs, and can negotiate spider webs. When disturbed, the exceptionally long antennae, longer than the forewing, wave alternately back and forth almost continually. The flight period extends from early April until the end of August, with a protracted emergence.

DNA barcoding confirmed the species identity of the dead larva. A 658 basepair barcode was obtained using Oxford Nanopore Technologies sequencing and released as GenBank accession PP391031. The sequence is identical to barcodes from specimens from Georgia, Croatia, and the United States, meaning that only a single COI-5P haplotype is known worldwide, and the new sequence is only the fourth known DNA sequence for the species. The barcode is 7.37% pairwise divergent from sequences of T. rhenania from France and Austria. The remarkable genetic uniformity across such widely separated populations suggests the species has been introduced more widely, at least to the USA, and probably also to Australia and South Africa, where it was historically recorded under different names before being synonymised.

The study also reviews the moth’s worldwide distribution, reporting new records for Lebanon and Syria. Historical introductions were temporarily established in Australia, where five examples were collected in New South Wales between 1879 and 1885 and the species is now thought possibly extinct, and in South Africa, where it was described from Cape Town. In Europe, the species is recorded from Madeira, the Azores, the Canaries, northern Spain, France, Germany, the Netherlands, Croatia, Greece, and Poland, with records from Turkey and Israel verified by dissection. Some records from Austria, Switzerland, Bulgaria, and Romania possibly represent misidentifications of T. rhenania, and a partial DNA barcode from Italy on the Barcode of Life Database represents a clear misidentification belonging to that species.

The taxonomic placement of the genus Tenaga, containing only two closely related species, remains debated. Some works retain it in the family Tineidae, subfamily Meessiinae, while Meessiidae has recently been elevated to family status based on molecular phylogenetics. The authors keep Tenaga conservatively in Tineidae, noting that the scavenging lifestyle suggested here is quite out of place for known Meessiidae, whilst it is not unusual for some Tineidae, especially the Tineinae and Hieroxestinae. The larva shows no synapomorphic characters with Meessiidae, such as anal combs for frass flicking, whereas like the Tineinae the pupa has dorsal abdominal spines. The DNA barcode alone is insufficient to place the species with certainty beyond its clear relationship with T. rhenania. The finding of T. nigripunctella and the partial elucidation of its life history in Great Britain is therefore of potential taxonomic as well as key biological interest, and more sequence data from other genes, together with detailed study of the early stages, will be needed to confirm the phylogenetic placement of this enigmatic genus.

Subject of Research: Biology and early stages of the tineid moth Tenaga nigripunctella

Article Title: First early-stage observations for Tenaga Clemens, 1862 with notes on biology and distribution of T. nigripunctella (Haworth, 1828) ( Lepidoptera , Tineidae )

Article References: Sterling, P. H., Stockwell, J., Oughton, J., & Lees, D. C. (2025). First early-stage observations for Tenaga Clemens, 1862 with notes on biology and distribution of T. nigripunctella (Haworth, 1828) (Lepidoptera, Tineidae). Nota Lepidopterologica, 48, 277-288. https://doi.org/10.3897/nl.48.124083

Image Credits: AI Generated

DOI: 10.3897/nl.48.124083

Keywords: Lepidoptera, Tineidae, Tenaga nigripunctella, snail shells, DNA barcoding, Dorset, larval biology, detritivory, Cornu aspersum, Meessiidae, First, early-stage

Triple-negative breast cancer, defined by the absence of estrogen receptor and progesterone receptor expression and the lack of HER2 amplification, accounts for roughly 10 to 15 percent of all breast cancers but carries a disproportionate share of early recurrences and deaths. Because the tumor lacks the molecular targets that make other breast cancer subtypes vulnerable to endocrine therapy or HER2-directed drugs, cytotoxic chemotherapy has remained the backbone of treatment. Historically, anthracycline-and-taxane regimens have been the standard of care, producing pathologic complete response rates of roughly 37 to 41 percent. When patients achieve a pathologic complete response, meaning no residual invasive cancer is found in the breast or lymph nodes at the time of surgery, their five-year event-free survival approaches 90 percent, compared with 57 percent for those who do not. That makes the response a powerful surrogate for cure and a critical endpoint for evaluating treatment strategies.

The trouble with anthracyclines lies in what they leave behind. Pooled data from randomized controlled trials show that patients treated with anthracycline-containing regimens face more than a five-fold higher risk of clinical cardiotoxicity, as well as sharply elevated risks of acute myeloid leukemia and myelodysplastic syndrome. Long-term follow-up studies in breast cancer survivors have documented heart failure, arrhythmias, and secondary blood cancers years or decades after the original diagnosis. For young women facing the prospect of decades of survival after successful breast cancer treatment, these late effects are not trivial side effects; they are life-altering or life-shortening complications in their own right. Reducing or eliminating anthracycline exposure without sacrificing cancer control has therefore become one of the most consequential questions in early breast cancer management.

At the same time, the treatment landscape has been transformed by two major developments. The first is the incorporation of carboplatin, a platinum chemotherapy agent, into neoadjuvant regimens. Trials such as GeparSixto, CALGB 40603, and BrighTNess demonstrated that adding carboplatin increases pathologic complete response rates in triple-negative disease, although often at the cost of substantially more hematologic toxicity, treatment delays, and dose reductions. The second development is immunotherapy. The landmark KEYNOTE-522 trial established perioperative pembrolizumab, an antibody that blocks the PD-1 immune checkpoint, combined with neoadjuvant chemotherapy as the new standard of care for stage II and III disease, improving both pathologic complete response and overall survival. Yet real-world experience with that regimen has revealed higher-than-anticipated immune-related adverse events, frequent discontinuation, and dose reductions, raising concerns about how much drug burden patients can realistically tolerate.

Against this shifting backdrop, a research team led by investigators at the University of Iowa and the University of Wisconsin, working with the Greater Plains Collaborative, a PCORnet clinical research network spanning ten medical centers across nine states, asked a deceptively simple question: in actual clinical practice, does adding anthracyclines to carboplatin plus taxane chemotherapy improve outcomes? They compared two regimens among women with stage I to III triple-negative breast cancer diagnosed between 2012 and 2024. The first, abbreviated CbT, consisted of carboplatin plus a taxane. The second, AC-CbT, added doxorubicin plus cyclophosphamide, the classic anthracycline combination. The primary outcome was pathologic complete response as recorded in hospital cancer registries by treating physicians, supplemented where necessary by comparisons of pre-treatment clinical staging and post-surgical pathologic staging.

The results were striking in their clarity. Among the 878 women analyzed, 41.2 percent received the anthracycline-free CbT regimen and 58.8 percent received AC-CbT. Half of the entire cohort achieved a pathologic complete response. On the surface, the anthracycline group appeared to fare slightly better, with response rates of 51.9 percent versus 47.2 percent for CbT, but this difference was not statistically significant. More importantly, after multivariable adjustment using inverse probability weighting, accounting for age, stage, grade, race, body mass index, comorbidity, treatment site, and pembrolizumab use, the addition of anthracyclines conferred no meaningful advantage, with an adjusted odds ratio of 1.05 and a confidence interval spanning 0.69 to 1.59. Sensitivity analyses that reclassified ambiguous response data or excluded those cases entirely produced the same conclusion.

What did predict response? Pembrolizumab use nearly doubled the odds of pathologic complete response, with an adjusted odds ratio of 1.97. Higher-grade tumors were more likely to respond, paradoxically, with grade 3 disease carrying nearly twice the odds of grade 1 or 2 tumors, a pattern consistent with the principle that the most biologically aggressive cancers are often the most sensitive to chemotherapy. Lower stage predicted higher response, as expected, and women diagnosed between ages 40 and 49 were roughly twice as likely to respond as those diagnosed at 60 or older, a finding the investigators probed extensively with post hoc and machine-learning analyses without uncovering an obvious explanation. Notably, an interaction analysis showed no evidence that anthracyclines mattered more or less depending on whether pembrolizumab was given, suggesting the anthracycline question remains unresolved in both the immunotherapy era and outside it.

The study also documents a dramatic practice transformation. Among all 2,413 triple-negative breast cancer patients in the underlying dataset, use of any carboplatin-containing regimen rose from 7.1 percent in 2012 to 72.8 percent in 2024. Pembrolizumab uptake was swift following the 2021 publication of KEYNOTE-522 results, and by the end of the study period, 46 percent of the analytic cohort had received it, concentrated overwhelmingly in the anthracycline-containing group. Interestingly, the data reveal how oncologists tailor care in the real world: older patients and those with comorbidities were more likely to forgo anthracyclines, while those with stage III, more aggressive disease were more likely to receive all four cytotoxic drug classes. Nearly a third of patients received combinations that had never appeared in clinical guidelines, reflecting deliberate individualized risk-benefit balancing rather than rigid protocol adherence.

Perhaps most provocative is the finding that carboplatin has penetrated into stage I disease, a population excluded from KEYNOTE-522 and still recommended anthracycline-taxane therapy by National Comprehensive Cancer Network guidelines. Among all stage I patients in the dataset, 19.4 percent received carboplatin, rising from 3.4 percent in 2012 to 41.7 percent in 2024. Within the analytic cohort, stage I patients showed similar response rates with or without anthracyclines. This off-guideline adoption finds precedent in the adjuvant PATTERN trial, in which carboplatin plus paclitaxel matched anthracycline-based therapy in five-year overall survival, with three-quarters of enrolled patients having node-negative disease.

The investigators are careful to acknowledge limitations. As an observational study relying on electronic health records and registry data, it cannot exclude unmeasured confounding, and variables such as performance status, BRCA mutation status, treatment toxicity, adherence, and relative dose intensity were unavailable. Lower delivered doses in the four-drug regimen could theoretically explain the lack of anthracycline benefit, although the authors argue that real-world tolerability is itself a legitimate measure of a regimen’s worth. The cohort also lacked racial diversity, and a notable fraction of responses were classified as “not otherwise specified,” though sensitivity analyses confirmed the robustness of the central finding.

Even with those caveats, the study represents, to the authors’ knowledge, the largest real-world analysis of triple-negative breast cancer spanning the immunotherapy era, and it provides the strongest real-world evidence yet that anthracyclines may not earn their place alongside carboplatin-based chemoimmunotherapy. Ongoing randomized trials, most notably the SCARLET trial evaluating anthracycline-free chemoimmunotherapy against the full KEYNOTE-522 regimen, will determine whether anthracycline omission can be definitively declared noninferior. Until then, this research shifts the burden of proof: the question is no longer whether patients can safely be spared anthracyclines, but whether the drugs still have anything left to offer.

Subject of Research: Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes

Article Title: Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes

Article References: Kroll, M. R., Schroeder, M. C., Neuner, J. M., Viyyuri, B. R., Ravindra, A., McDougall, D., Chapman, C. G., Fleege, N. M. G., Chrischilles, E. A., Song, X., & Phadke, S. (2026). Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. Breast Cancer Research and Treatment, 219(2), Article 7. https://doi.org/10.1007/s10549-026-08071-8

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08071-8

Keywords: Anthracycline-containing, versus, anthracycline-free, carboplatin-based, regimens, early-stage, triple-negative, breast, cancer, real-world, outcomes, scientific research